How hacked is hacked? Heres a hack scale to better understand the SolarWinds cyberattacks – GeekWire

(BigStock Photo)

Microsoft, FireEye, and the U.S. Treasury department have been hacked in the SolarWinds attacks.

This statement is true but doesnt tell the whole story accurately.

Its true because by most peoples understanding, these organizations have been hacked. But it doesnt tell the whole story accurately because each of these organizations has had different impacts with different levels of severity from the hack.

A good example of why this matters is how we talk about cancer. Years ago having cancer was a binary thing, too. Either you had cancer and were going to die or you didnt. And cancer was often talked about in hushed tones with euphemistic terms the C word.

Because of advances in medicine, this is no longer the case: people can and do survive cancer. So now we talk about cancer more openly in a way that reflects that reality in terms of types of cancer and stages. That helps us understand if its a kind of cancer that could be treatable and survivable or one that is untreatable and terminal.

The same is true now about being hacked. Some hacking is catastrophic, but some is survivable. We see this reality in the different reports coming out about SolarWinds hacks. Some organizations are severely affected while others less so. But these crucial nuances are lost when we say theyve all been hacked.

There is no hacked scale that is used by professionals, let alone that can be used by laypeople. This is one reason why we continue to just hear about hacked.

If were going to understand the nuances in the SolarWinds cases better, we need to define a scale. Since the most important thing in hacks is the spread and severity, the cancer staging system gives a good model to adapt because it tracks the spread and severity of cancer in five stages. We can do the same with hacks.

The key factors in these levels are the attackers access and control: less of each is better, more is worse.

For instance, SolarWinds has said that 18,000 customers were impacted. But this doesnt mean that 18,000 customers networks experienced Stage IV and are fully and totally controlled by the attackers.

The information SolarWinds provides only tells us that those customers experienced Stage 0: the attackers may have had a way to get further into the network. To know if attackers did go further and customers were more severely affected requires more investigation.

On Dec. 17, Microsoft said it can confirm that we detected malicious Solar Winds binaries in our environment, which we isolated and removed we have not found evidence of access to production services or customer data. Our investigations, which are ongoing, have found absolutely no indications that our systems were used to attack others. Taking the information at face value, that would seem to indicate that Microsoft experienced Stage 0 or Stage I.

FireEye made a disclosure on Dec. 8 of its own compromise that would turn out to be part of the SolarWinds attacks. It seems to indicate that the attacker was able to steal information but gave no indication that the attackers were able to alter data or gain administrative control of the network, likely making what the company experienced a Stage II.

Details of the U.S. Treasurys attack arent as clear in part because we only have the information second and third-hand. The information in the New York Times report clearly indicates that the attackers at least had read access on the network, which is consistent with Stage II. However, some of the details that have emerged about how the attackers may have gained access to cloud properties imply the possibility that the attackers had achieved Stage IV on the network.

The goal with any scale is to make things simple but not simplistic. But no scale is ever perfect; there are always going to be ways that scales can obscure critical details. The important thing with scales like this is to enable us to easily and succinctly understand the relative comparative severity of the situation. What we know does indicate that the Treasury situation is worse than the Microsoft or FireEye situations in this regard, this scale is accurate and useful.

The key point for everyone now is to understand that hacked isnt a simple binary state: there are different degrees of it. By understanding this we can better assess how serious a situation is and what we need to do in response.

The rest is here:

How hacked is hacked? Heres a hack scale to better understand the SolarWinds cyberattacks - GeekWire

Nanomedicine Market With Size, Status, Demand, Current And Future Investments Forecast Till 2026: GE Healthcare, Johnson & Johnson, Mallinckrodt…

WMR added the Most up-to-date research on Nanomedicine Market Forecast to 2026 to its huge collection of research reports database. An insight into the important factors and trends influencing the market competition and opportunities in Investment. This Report compiled byWorldwide Market Reports features a succinct analysis of the latest market trends.

Nanomedicine market reports provide a comprehensive overview of the global market size and share. Nanomedicine market data reports also provide a 5 year pre-historic and forecast for the sector and include data on socio-economic data of global. Key stakeholders can consider statistics, tables & figures mentioned in this report for strategic planning which leads to the success of the organization.

Request a sample copy at: https://www.worldwidemarketreports.com/sample/205987

New business opportunities and rising demand for Nanomedicine market activates are the primary factors expected to drive the growth of the Nanomedicine market in the United States, EU, Japan, China, India, Africa, Southeast Asia are the major region leading the Nanomedicine market.

The major players profiled in this report include

Impact of COVID-19:

Nanomedicine Market report analyses the impact of Coronavirus (COVID-19) on the Nanomedicine industry. Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 180+ countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Nanomedicine market in 2020.

COVID-19 can affect the global economy in 3 main ways: by directly affecting production and demand, by creating supply chain and market disturbance, and by its financial impact on firms and financial markets.

Further in the Nanomedicine Market research reports, following points are included along with in-depth study of each point:

Production Analysis: Production of the Nanomedicine is analyzed with respect to different regions, types, and applications. Here, price analysis of various Nanomedicine Market key players is also covered.

Supply and Consumption: In continuation with sales, this section studies supply and consumption for the Nanomedicine Market. This part also sheds light on the gap between supply and consumption. Import and export figures are also given in this report.

Key Strategic Developments: The study also includes the key strategic developments of the Nanomedicine market, comprising R&D, new product launch, M&A, agreements, collaborations, partnerships, joint ventures, Global and regional growth of the leading competitors operating in the market on a global and regional scale.

Get Sample ToC to understand the CORONA Virus/COVID19 impact and be smart in redefining business strategies.https://www.worldwidemarketreports.com/covidimpact/205987

In this report, the global Nanomedicine market is valued at USD XX million in 2019 and is expected to reach USD XX million by the end of 2026, growing at a CAGR of XX% between 2019 and 2026.

The report provides an in-detail list of drivers and restraints in the market, which are influencing the market growth. Additionally, provides expected opportunities and emerging trends in the market.

The report includes a detailed study of Porters Five Forces model to analyze the different factors affecting the growth of the market. Moreover, the study also covers a market attractiveness analysis, PESTLE analysis, Value Chain Analysis, and SWOT analysis. The report also includes detailed abstracts about statistics, revenue forecasts, and market valuation, which additionally highlights its status in the competitive landscape and growth trends accepted by major industry players.

The report is a collection of first-hand information, qualitative assessment by industry analysts, and inputs from industry experts. Moreover, the report also maps the qualitative impact of various market factors on market segments and geographies. The major factor driving the adoption of Nanomedicine is the formation of a data encryption feature and data privacy feature. The major industry changing factors for the Nanomedicine market segments are explored in this report. This report also covers the growth factors of the global market based on end-users.

Benefits of Purchasing Nanomedicine Market Report:

Analyst Support: Get your query resolved from our expert analysts before and after purchasing the report.

Customers Satisfaction: Our expert team will assist with all your research needs and customize the report.

Inimitable Expertise: Analysts will provide deep insights into the reports.

Assured Quality: We focus on the quality and accuracy of the report.

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Nanomedicine market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares split, and breakdowns have been determined using secondary sources and verified primary sources.

*If you have any special requirements, please let us know and we will offer you the report as you want.

** The Values marked with XX is confidential data. To know more about CAGR figures fill in your information so that our business development executive can get in touch with you.

Place an Enquiry Before buying Nanomedicine Market Report 2026: https://www.worldwidemarketreports.com/quiry/205987

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends.

See the original post here:

Nanomedicine Market With Size, Status, Demand, Current And Future Investments Forecast Till 2026: GE Healthcare, Johnson & Johnson, Mallinckrodt...

Nanomedicine Market Forecast Estimation & Approach 2020-2026 | GE Healthcare, Johnson & Johnson, Mallinckrodt plc, Merck & Co. Inc.,…

The Global Nanomedicine Market report provides information by Top Players, Geography, End users, Applications, Competitor analysis, Sales, Revenue, Price, Gross Margin, Market Share, Import-Export, Trends and Forecast.

Initially, the report provides a basic overview of the industry including definitions, classifications, applications, and industry chain structure. The Nanomedicine market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.

To Get Copy of Sample Report Kindly Connect with us https://www.affluencemarketreports.com/industry-analysis/request-sample/894345/

2020 Global Nanomedicine Market Report is a professional and in-depth research report on the worlds major regional market conditions of the Nanomedicine industry, focusing on the main regions and the main countries (United States, Europe, Japan and China).

Global Nanomedicine market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer.

The Top players are

Nanomedicine Market Report based on Product Type:

Nanomedicine Market Report based on Applications:

Get Extra Discount on Nanomedicine Market Report, If your Company is Listed in Above Key Players List @ https://www.affluencemarketreports.com/industry-analysis/request-discount/894345/

The report introduces Nanomedicine basic information including definition, classification, application, industry chain structure, industry overview, policy analysis, and news analysis. Insightful predictions for the Nanomedicine market for the coming few years have also been included in the report.

The report focuses on global major leading Nanomedicine Market players providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out.

The Nanomedicine industry development trends and marketing channels are analyzed. Finally, the feasibility of new investment projects is assessed, and overall research conclusions offered.

ENQUIRE MORE ABOUT THIS REPORT @ https://www.affluencemarketreports.com/industry-analysis/request-inquiry/894345/

CHAPTERS COVERED IN THIS REPORT ARE AS FOLLOW:

Chapter 1: Nanomedicine Market Overview, Product Overview, Market Segmentation, Market Overview of Regions, Market Dynamics, Limitations, Opportunities and Industry News and Policies.

Chapter 2: Nanomedicine Industry Chain Analysis, Upstream Raw Material Suppliers, Major Players, Production Process Analysis, Cost Analysis, Market Channels and Major Downstream Buyers.

Chapter 3: Value Analysis, Production, Growth Rate and Price Analysis by Type of Nanomedicine.

Chapter 4: Downstream Characteristics, Consumption and Market Share by Application of Nanomedicine.

Chapter 5: Production Volume, Price, Gross Margin, and Revenue ($) of Nanomedicine by Regions (2014-2020).

Chapter 6: Nanomedicine Production, Consumption, Export and Import by Regions (2014-2020).

Chapter 7: Nanomedicine Market Status and SWOT Analysis by Regions.

Chapter 8: Competitive Landscape, Product Introduction, Company Profiles, Market Distribution Status by Players of Nanomedicine.

Chapter 9: Nanomedicine Market Analysis and Forecast by Type and Application (2020-2026).

Chapter 10: Market Analysis and Forecast by Regions (2020-2026).

Chapter 11: Industry Characteristics, Key Factors, New Entrants SWOT Analysis, Investment Feasibility Analysis.

Chapter 12: Market Conclusion of the Whole Report.

Chapter 13: Appendix Such as Methodology and Data Resources of This Research.

For More Details on Impact of COVID-19 on Nanomedicine Market https://www.affluencemarketreports.com/industry-analysis/covid19-request/894345/

About Affluence:

Affluence Market Reports is the next generation of all your research needs with a strong grapple on the worldwide market for industries, organizations, and governments. Our aim is to deliver exemplary reports that meet the definite needs of clients, which offers an adequate business technique, planning, and competitive landscape for new and existing industries that will develop your business needs.

We provide a premium in-depth statistical approach, a 360-degree market view that includes detailed segmentation, key trends, strategic recommendations, growth figures, Cost Analysis, new progress, evolving technologies, and forecasts by authentic agencies.

For more Details Contact Us:

Affluence Market Reports

Contact Person: Mr. Rohit

Phone Number: U.S +1-(424) 256-1722

Email: [emailprotected]

Website: http://www.affluencemarketreports.com

More:

Nanomedicine Market Forecast Estimation & Approach 2020-2026 | GE Healthcare, Johnson & Johnson, Mallinckrodt plc, Merck & Co. Inc.,...

IKBFU Scientists Develop a Plant-Based Technology for Obtaining Magnetic Nanoparticles with Antifungal Properties – QS WOW News

A team of researchers from obtained magnetic nanoparticles using a sweet flag (Acorus calamus). Both the roots and the leaves of this plant have antioxidant, antimicrobial, and insecticide properties. The extract of the sweet flag was used as a non-toxic reagent for the manufacture of coated particles.

The authors of the work also showed the efficiency of the new nanoparticles against several types of pathogenic fungi that damage cultivated plants. A technology developed by the team provides for the manufacture of nanoparticles from a cheap plant-based raw material and reduces the harmful effect of reagents on the environment. The results of the study were publishedin theNano-Structures & Nano-Objectsjournal.

Because of their unique properties, nanoparticles are used in many areas, from medicine to oil production. Their characteristics depend to a great extent on their size and shape, and the ratio between their surface area and volume plays a key role. The bigger it is, the stronger is a nanoparticles local effect.

Magnetic nanoparticles that can be controlled with an external magnetic field or emit heat under the influence of electromagnetic radiation have potential in biology and medicine. For example, particles with increased magnetic moment are used both in medical diagnostics and for the treatment of various conditions. Some studies also indicate that magnetic nanoparticles can have antifungal properties. For these applications, scientists suggest using barium ferrite nanoparticles in the biocompatible coating.

There are several methods of manufacturing coated nanoparticles with given characteristics, but all of them include toxic reagents. We have developed an environmentally friendly technology for the production of barium ferrite with the use of sweet flag extract. The surface of these particles has additional biological properties and the particles themselves possess all necessary magnetic and geometrical characteristics, said Prof. Larissa Panina, a Ph.D. in Physics and Mathematics from BFU.

The team mixed an extract made from dried sweet flag roots with barium and iron salts and water. Then, the mixture was heated to evaporate the liquid and obtain powder. After that, the powder was sintered at temperatures up to 900C, and nanoparticles were formed.

To study their morphology, the team used scanning electron microscopy. This method is based on scanning the surface of a studied object with an electron beam and applies to fragments that are just several nanometers in size. The average size of the hexagon-shaped nanoparticles was from 20 to 50 nm. The team also studied the crystalline structure and elemental composition of the particles using X-ray structural analysis and energy dispersive spectroscopy and found out that the new particles had no admixtures.

The barium ferrite nanoparticles synthesized by the team were active against four species of fungi that cause various diseases of fruit and flowering plants. Even in small concentrations, the nanoparticles were able to slow down the growth of pathogens. In the course of the Fenton reaction, the ions of iron in barium ferrite reacted with peroxides and reactive oxygen forms (OH radicals) appeared.

Being extremely active, they reacted with substances in harmful cell walls, damaged them, and thus slowed down the growth of pathogens. According to the authors of the study, this is a universal mechanism that might make the nanoparticles active against other species of fungi, too.

Read the rest here:

IKBFU Scientists Develop a Plant-Based Technology for Obtaining Magnetic Nanoparticles with Antifungal Properties - QS WOW News

Antibacterial Nanorobots Market Improvement, Orientation and Forecast from 2020-2026| Bruker, JEOL, Thermo Fisher – Farming Sector

LOS ANGELES, United States: The report titled, Global Antibacterial Nanorobots Cartons Market Report, History and Forecast 2015-2026 has been recently published by QY Research. The authors of the report have done extensive study of the global Antibacterial Nanorobots Cartons market keeping in mind the key aspects such as growth determinants, opportunities, challenges, restraints, and market developments. This analysis will enrich the ability of the companies involved in the global Antibacterial Nanorobots Cartons market to make precise decisions. The report also emphasizes on the current and future trends in the global Antibacterial Nanorobots Cartons market, which may bode well for the global Antibacterial Nanorobots Cartons market in the coming years. Impact of the driving factors on the global Antibacterial Nanorobots Cartons market growth has been mapped by the report. Besides, factors that are likely to challenge the global Antibacterial Nanorobots Cartons market growth in the years to come are discussed by the industry experts in the report.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) https://www.qyresearch.com/sample-form/form/2217972/global-antibacterial-nanorobots-sales-market

The report thoroughly reviews the manufacturers operating in the global Antibacterial Nanorobots Cartons market. It offers figures pertaining to revenue, productions, and market share to provide a 360-degree view of it. They have used SWOT analysis to assess internal strengths, weaknesses, external opportunities, and threats. This is expected to help readers understand finer nuances of the market. This research report is presented in such a way that it helps a reader comprehend the market in wider aspects. In order to fulfil that goal, the researchers have divided the report into various chapters. It will provide readers with accurate and exact information, necessary for complete understanding of the market.

Key Players Mentioned in the Global Antibacterial Nanorobots Market Research Report: Bruker, JEOL, Thermo Fisher, Ginkgo Bioworks, Oxford Instruments, Imina Technologies, Toronto Nano Instrumentation, Klocke Nanotechnik, Kleindiek Nanotechnik, Park Systems

Global Antibacterial Nanorobots Market by Type: 50-100 nm, > 100nm

Global Antibacterial Nanorobots Market by Application: Nanomedicine, Biomedical Science

The researchers have covered the various product type, end user, and application segments in the Global Antibacterial Nanorobots Cartons Market Report. They have studied the varieties of products available in the market. Assessment of investments and innovation in these products has also been mentioned in complete detail. The application segment also receives spotlight through evaluation of possible usages of products.

The regions covered in the Antibacterial Nanorobots Cartons Market Report includes Asia Pacific, South Asia, the Middle East and Africa, North America, South America, and Europe. The research report analyses all the factors augmenting each regional market. It provides the historic, current, and forecast figures for them. Changing government policies and political volatility have been discussed at great length in this chapter to offer clarity.

Questions Answered by the Report:

Which are the dominant players of the global Antibacterial Nanorobots market?What will be the size of the global Antibacterial Nanorobots market in the coming years?Which segment will lead the global Antibacterial Nanorobots market?How will the market development trends change in the next five years?What is the nature of the competitive landscape of the global Antibacterial Nanorobots market?What are the go-to strategies adopted in the global Antibacterial Nanorobots market?

Request for customization in Report: https://www.qyresearch.com/customize-request/form/2217972/global-antibacterial-nanorobots-sales-market

Table of Contents

About Us:

QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), experts resources (included energy automotive chemical medical ICT consumer goods etc.

Follow this link:

Antibacterial Nanorobots Market Improvement, Orientation and Forecast from 2020-2026| Bruker, JEOL, Thermo Fisher - Farming Sector

These Nature-Inspired Solutions Could Be The Key To A More Sustainable Future – Tatler Philippines

By Relaxnews December 28, 2020

Climate change and biodiversity loss are laying bare our dependence on the natural world for everything from the food we eat to the air we breathe.

Sign up for our newsletters to get all our top stories delivered.

You've Successfully Subscribed

Climate change and biodiversity loss are laying bare our dependence on the natural world for everything from the food we eat to the air we breathe.

But nature also holds the solution to other problems, inspiring scientific discovery in a host of unexpected ways.

Nature is "a source of inspiration for science, because it has figured out the way Earth supports life," said Lex Amore from the Biomimicry Institute.

"It is imperative we look to the biological blueprints that have been successful over millennia to launch groundbreaking ideas faster."

From smelly durian fruit that could charge electric cars to sea sponges that might help build better spaceships, here is a selection of this year's scientific work inspired by nature.

Read also: What Is "Ecocide" And Should It Be A Crime?

Removing tumours and blood clots through minimal invasive surgery may soon become easier thanks to a flexible, ultra-thin and steerable needle inspired by parasitic wasps.

These formidable insects inject their eggs into living hosts such as caterpillars through a hollow needle called the ovipositor.

Scientists from the Delft University of Technology in the Netherlands studied the ovipositor's delivery mechanism, with blades that slide up and down alternately, using friction to push the eggs through.

Researchers designed a needle made up of sliding rods that imitate the ovipositor, according to a recent study in Frontiers in Bioengineering and Biotechnology.

They say the new needle is capable of reaching deeply buried parts of the body to inject medicine or remove harmful formations, while minimising trauma and patient recovery time.

This is a starkly different outcome than for the targets of parasitic wasps, whose larva often devour their caterpillar host from the inside.

Spiders make silk to entangle unsuspecting bugs, but now humans can use it to make optical lenses capable of picturing viruses that are invisible to the naked eye.

In a June study published in the Journal of Applied Physics, scientists said they used daddy-long-legs' dragline silk -- which makes a web's frame -- as a support for the lens.

In experiments, they covered a strand of spider silk in wax then dripped resin onto it. As it condensed, the silk naturally formed a dome, which researchers baked in an ultraviolet oven.

The resulting optical lens is about the size of a red blood cell and could be used to picture nano-scale objects like viruses or the insides of biological tissue.

As the lens is made from natural, non-toxic material, it can safely be used inside the body.

Read also: 3 Ways To Make Your Home Environmentally Sustainable

An intricately latticed marine sponge called the Venus' flower basket found in the depths of the Pacific Ocean could inspire stronger skyscrapers, longer bridges and lighter spacecraft, according to a September study published in Nature Materials.

Scientists discovered that the structure of the sponge's tubular skeleton gives it a higher strength-to-weight ratio than traditional designs that have been used for centuries for buildings and bridges.

"We've been studying structure-function relationships in sponge skeletal systems for more than 20 years, and these species continue to surprise us," said co-author James Weaver, a Harvard University scientist.

To some they are succulent and delicious, to others they are so overpoweringly stinky that they are routinely banned from hotel rooms across Southeast Asia.

But the durian fruit may be about to add a new unexpected reason for its fame -- helping to charge mobile phones and electric cars.

In a February study published in the Journal of Energy Storage, scientists described how they made extremely light and porous materials called aerogels from the fruit.

Aerogels are "great super-capacitors", which resemble energy reservoirs that dole out energy smoothly, said co-author and Sydney University associate professor Vincent Gomes.

"(Super-capacitors) can quickly store large amounts of energy within a small battery-sized device," he said.

They can then supply energy to charge electronic devices such as mobile phones, tablets and laptops within a few seconds, he added.

Read also: World Wildlife Fund PH: The New Normal Must Become A Green One

Cars, aeroplanes and buildings are mostly made of steel, concrete or brick.

Bamboo has attracted interest as a versatile construction material. But how to make it strong enough? In a May study published in the ACS Nano, researchers said they had found an answer.

By partially removing the lignin -- an organic substance which forms woody tissue -- and microwaving the bamboo, researchers said its strength nearly doubled.

Bamboo is already used to build houses and bridges, but this new discovery may further increase its popularity as a light, fast-growing and sustainable alternative to polluting materials.

From forests to the depths of the oceans, Amore from the Biomimicry Institute said there was "so much intelligence" to tap into in the natural world.

"We can use biomimicry, this practice of studying nature and replicating its strategies in design, to not only learn from nature's wisdom, but also heal ourselves -- and this planet -- in the process."

Originally posted here:

These Nature-Inspired Solutions Could Be The Key To A More Sustainable Future - Tatler Philippines

OPINION: Colorful words overemphasize the obvious – Arkansas Online

I'm back again with random thoughts blowing around my brain. Is that what headwinds are?

People have a strange habit when they're describing the color of things.

I'm looking for a car that's blue in color.

Blue in color. What else could the blue signal? Could it be blue in taste? Blue in sound? I'm sure it's not blue in mood.

From the wine pages of The Washington Post: "The 1982 Montbray Cabernet Sauvignon was brick red in color yet still bright and alive on the nose and palate, with spice-box aromas of clove, pepper and fenugreek."

(Wine writing is so, so fancy.)

So the wine is brick red in color and not in flavor? Not in composition?

One reader wrote to the food staff of The Post about the fruit of a quince bush in her yard.

It's small, and yellow in color, and frankly, over the years, I've just let it fall to the ground without doing anything with it.

Yellow in color? Not yellow in terms of cowardice?

The craziest example of all was from a story about football uniforms.

They'll have a darker burgundy jersey, and pants that are actually gold in color.

So, the pants aren't made of the element gold? Thanks for that clarification.

Similarly, an article in The Post recommending wrapping baked goods in colorful red, blue, green and gold cellophane.

I have never seen uncolorful or colorless red cellophane, have you?

We have all heard of smallpox. The sometimes deadly disease, also called variola, causes eruptions on the skin that can leave a person with pockmarks. We don't need to worry about catching it now because vaccines have eradicated it, though it had been around for many centuries.

"Currently, there is no evidence of naturally occurring smallpox transmission anywhere in the world," the National Institute of Allergy and Infectious Diseases reports.

But the American Heritage Dictionary definition got weird. The disease is called smallpox to contrast it to the great pox, which was syphilis. The sexually transmitted disease causes larger pockmarks. (Please trust me when I urge you not to search on Google for images of syphilis. I sincerely regret having done so.) The great pox spread across Europe in the 15th and 16th centuries.

Because we've been hearing about vaccines every day for months now, I'll inject a bit of history. Smallpox was the virus that inspired the first vaccine that worked.

The World Health Organization explains: "The smallpox vaccine, introduced by Edward Jenner in 1796, was the first successful vaccine to be developed. He observed that milkmaids who previously had caught cowpox did not catch smallpox and showed that inoculated vaccinia protected against [the] virus."

These two words have most of the same letters, but they have different meanings. The difference has grown a little hazy over the years.

Alternately means some things happen by turns. First one, then the other, then back again to the first.

She watched parts of two TV shows alternately because she didn't have a DVR.

The team alternately practices at two high school baseball fields.

Alternatively is following a path other than the original option.

He asked me to phone him. Alternatively, I sent him a text.

We could have Key lime pie. Alternatively, we could have chocolate mousse pie.

(Please note that the much shorter word or could easily replace alternatively.)

Similarly, less conventional music is called alternative music. Alternative medicine offers treatments not found in the mainstream. And, though we see fewer and fewer newspapers each month, an alternative newspaper might offer less formal content and writing style. All three cases offer a different option.

People often use alternate when they mean alternative. From The Post:

The United States risks being left behind by other countries if it doesn't develop alternate energy technologies.

Instead, the writer meant the country needs a different energy source.

Legal proceedings use alternate when describing juries, but alternative is more accurate.

The next day, the 12 jurors and two alternate jurors settled into their jury sections and the proceedings began.

Those two jurors are other options.

Authorities sometimes suggest using a different route from the normal one. So alternative is needed here:

Officials warned drivers to expect delays, saying they might need to use alternate routes.

Naturally, as I often note, things change. Merriam-Webster says alternative is a synonym for alternate, partly because more and more people are using alternate when they mean alternative. Still, most people on the dictionary's Usage Panel say the two words are not synonymous. Each word has its place.

I'll confess that the pandemic has made it hard for me to feel rejuvenated for a while. Though chocolate does help.

When you would like to feel rejuvenated, you do something that makes you feel like your old self again. Or you might rejuvenate a weak football team, a crummy couch or a bad public image.

And yet, juvenate isn't a word. Normally, the prefix re- means something is happening again. I'm trying to find a philosophical reason behind this. You can be made young again, but you can't be made young? Maybe I'll stick with invigorate and reinvigorate.

A news guy this week was asking a guest to opine on some situation:

What's your analysis so far?

Your analysis sounds exactly like urinalysis.

I am so immature.

Sources include Merriam-Webster, National Institute of Allergy and Infectious Diseases, The American Heritage Dictionary, The Washington Post, Society for Applied Microbiology, the World Health Organization. Reach Bernadette at

bkwordmonger@gmail.com

Visit link:

OPINION: Colorful words overemphasize the obvious - Arkansas Online

Bionano Customer Praxis Genomics Accredited by College of American Pathologists, Completing First LDT in US for Constitutional Genetic Disorders that…

SAN DIEGO, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), announced today that Praxis Genomics, LLC received accreditation from the College of American Pathologists (CAP), making it the first CAP-accredited, CLIA-certified diagnostic lab in the United States to offer a laboratory developed test (LDT) based on whole genome analysis with Saphyr. The LDT is designed for postnatal patients suspected of a constitutional genetic disorder. Praxis uses optical genome mapping (OGM) with Bionanos Saphyr System as an alternative to traditional methods of chromosomal microarray (CMA) and karyotyping (KT), as they seek to improve the rate of clinical diagnosis for patients with genetic disease. CMA and KT together typically diagnose 30-50% of patients tested. Recent studies have found that OGM with Saphyr is concordant with CMA and KT and also diagnoses a significant fraction (18-25%) of the patients who could not be diagnosed with traditional methods.

Medical guidelines recommend successive rounds of analysis with CMA, KT, repeat expansion testing, single gene or gene panel testing and whole exome sequencing until a pathogenic variant is identified or until the different techniques have been exhausted. At Praxis, this tiered approach is replaced by whole genome analysis using OGM with Saphyr for structural variants (SVs) and, when requested, whole genome analysis by next-generation sequencing (NGS) for single nucleotide variants (SNVs). This workflow eliminates costly and time-consuming steps like cell culture and tedious manual data analysis across multiple platforms and provides a streamlined approach for detection of all types of genomic aberrations designed to achieve a higher rate of diagnosis faster, easier, and at a lower economic cost to labs and payors.

Several diagnostic labs in the U.S. such as PerkinElmer Genomics and the University of Iowa Hospitals and Clinics have already launched Saphyr based LDTs targeting a specific clinical indication, a form of muscular dystrophy called FSHD1. While development of whole genome clinical tests with Saphyr have been in progress in Europe for various clinical applications including inherited genetic disorders and leukemias, the Praxis clinical service is the first to provide whole genome analysis in the U.S.

Erik Holmlin, PhD, CEO of Bionano Genomics commented: We want to congratulate Praxis Genomics and its founder Dr. Peter L. Nagy on their CAP accreditation, making their Saphyr-based test the first whole genome analysis LDT in the U.S. in a CAP/CLIA setting. We believe this accreditation is a key step on the path to reimbursement of Saphyr-based LDTs by third party payors. While Praxis is first, we expect several other U.S. laboratories to offer whole genome LDTs for various clinical applications in the future, establishing Saphyr as a key tool for next generation cytogenomics. By adding whole genome sequencing, Praxis intends to demonstrate that Saphyr and NGS complement each other to provide answers to patients and families affected with genetic disorders. As more Saphyr-based tests enter the LDT stage worldwide, we believe it is possible to create a paradigm shift for cytogenomic applications in cancer and genetic disease that have the potential to improve patient outcomes.

Dr. Peter L. Nagy, Founder and CEO of Praxis Genomics will present case studies of diagnoses made with OGM at Bionanos Next-Generation Cytogenomics Symposium on January 11, 2021. Register for the event here: https://bit.ly/3fPULzs

About Bionano GenomicsBionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Bionanos Saphyr system is a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools, and genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. Lineagen has been providing genetic testing services to families and their healthcare providers for over nine years and has performed over 65,000 tests for those with neurodevelopmental concerns. For more information, visitwww.bionanogenomics.com or http://www.lineagen.com.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as may, will, expect, plan, anticipate, estimate, intend and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the capability of Praxis Genomics LDT to replace the tiered approach for detection of pathogenic variants currently recommended by medical guidelines; our expectations regarding reimbursement for Saphyr-based LDTs by third party payors; Saphyrs potential as a powerful new tool in cytogenetics and its potential contribution to improvements in traditional cytogenetics; Praxis Genomics intended use of the Saphyr system and our services, including to demonstrate Saphyrs capabilities in comparison to NGS; the ability to integrate data from the Saphyr system into other offerings by Praxis Genomics; expanded adoption and utilization of the Saphyr system for various clinical applications; improvements in patient outcomes driven by increased use of Saphyr-based tests in the LDT arena; and Saphyrs potential as an indispensable tool for personalized medicine and furthering understanding of cancer in the medical community. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the loss of key members of management and our commercial team; and the risks and uncertainties associated withour business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2019 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

CONTACTSCompany Contact:Erik Holmlin, CEOBionano Genomics, Inc.+1 (858) 888-7610eholmlin@bionanogenomics.com

Investor Relations Contact:Ashley R. RobinsonLifeSci Advisors, LLC+1 (617) 430-7577arr@lifesciadvisors.com

Media Contact:Darren Opland, PhDLifeSci Communications+1 (617) 733-7668darren@lifescicomms.com

Originally posted here:

Bionano Customer Praxis Genomics Accredited by College of American Pathologists, Completing First LDT in US for Constitutional Genetic Disorders that...

Chiesi Global Rare Diseases Announces First Patient Treated in Expanded Access Program for Pegunigalsidase Alfa for Proposed Treatment of Fabry…

- Program grants access to investigational therapy for Fabry disease patients in the United States who cannot be adequately treated with currently available FDA-approved drugs -

BOSTON, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare group (Chiesi Group), today announced the first patient has been treated in the Expanded Access Program (EAP) in the United States for pegunigalsidase alfa, currently in development for the treatment of Fabry disease. Treatment was initiated on December 21, 2020 by Ozlem Goker-Alpan, M.D., founder and Chief Executive Officer of the Lysosomal & Rare Disorders Research & Treatment Center (LDRTC) in Fairfax, Va, and Lauren Noll, Clinical Research Coordinator.

The initiation of treatment in the first patient enrolled in our EAP is an important milestone for the Fabry disease community and another reflection of our commitment to supporting patients, caregivers and their healthcare providers as they make important decisions about their health and disease management, said Giacomo Chiesi, Head of Chiesi Global Rare Diseases. Through this EAP, many patients can have access to treatment with pegunigalsidase alfa as we continue to work diligently to advance this therapy through the final stages of the regulatory review process in the months ahead. We would like to thank the Fabry patient and medical community for the support they have provided to us in the setup of this program.

The EAP is open to patients with a clinical diagnosis of Fabry disease who, in the opinion of the treating physician, have no comparable or satisfactory alternative treatment options with currently available FDA-approved therapies for Fabry disease. Other eligibility criteria apply. Patients participating in the EAP receive infusions of pegunigalsidase alfa every two weeks at 1mg/kg body weight. Information related to adverse events and other limited data will be collected from participants.

We are focused on providing patients with the widest possible range of options for high quality care, said Dr. Goker-Alpan. This is an exciting time for the Fabry disease community. We are pleased to participate in this EAP and will continue to support all efforts to help more patients have access to the treatments they need.

Pegunigalsidase alfa is an investigational product and currently not approved by the U.S. Food and Drug Administration (FDA). The effectiveness and safety of pegunigalsidase alfa have not been reviewed or approved by the FDA. Before FDA review and approval, no conclusions can be drawn on pegunigalsidase alfas efficacy and safety profile. When seeking expanded access, treating physicians should consider all possible risks of treatment with pegunigalsidase alfa. Access must be compliant with all applicable federal and state laws and regulations. Investigators should not seek reimbursement for product provided to patients who participate in a government-funded insurance program.

In November 2020, the FDA extended the Prescription Drug User Fee Act (PDUFA) date to April 27, 2021 for review of the Biologics License Application (BLA) seeking accelerated approval of pegunigalsidase alfa for the proposed treatment of adult patients with Fabry disease. Concurrently with the EAP, pegunigalsidase alfa is being evaluated in patients with Fabry disease under an open Investigational New Drug application in the Phase III BALANCE, BRIGHT and BRIDGE clinical trials and other related open label studies.

The Expanded Access Program is listed on ClinicalTrials.gov Identifier: NCT04552691 (https://clinicaltrials.gov/ct2/show/NCT04552691). Additional information on Chiesis Expanded Access policy is available at https://www.chiesiusa.com/sustainability/expanded-access-programs/. Treating physicians must submit requests on behalf of their patients for consideration via the EAP request portal at https://chiesi.versaic.com.

About Fabry Disease

Fabry disease is an X-linked inherited disease that results from deficient activity of the lysosomal GalactosidaseA enzyme resulting in progressive accumulation of abnormal deposits of a fatty substance called globotriaosylceramide (Gb3) in blood vessel walls throughout a person's body. Fabry disease occurs in one person per 40,000 to 60,000. Fabry patients inherit a deficiency of the GalactosidaseA enzyme, which is normally responsible for the breakdown of Gb3. The abnormal storage of Gb3 increases with time and, accordingly, Gb3 accumulates, primarily in the blood and in the blood vessel walls. The ultimate consequences of Gb3 deposition range from episodes of pain and impaired peripheral sensation to end-organ failure particularly of the kidneys, but also of the heart and the cerebrovascular system.

About Pegunigalsidase Alfa

Pegunigalsidase alfa is an investigational, plant cell culture-expressed, and chemically modified stabilized version of the recombinant -Galactosidase-A enzyme. Protein sub-units are covalently bound via chemical cross-linking using short PEG moieties.

About Chiesi Global Rare Diseases

Chiesi Global Rare Diseases is a business unit of the Chiesi Group established in February 2020 and focused on research and development of treatments for rare and ultra-rare disorders. The Global Rare Diseases unit works in collaboration with Chiesi Group to harness the full resources and capabilities of our global network to bring innovative new treatment options to people living with rare diseases, many of whom have limited or no treatments available. The unit is also a dedicated partner with global leaders in patient advocacy, research and patient care. For more information visit http://www.chiesiglobalrarediseases.com.

About Chiesi Group

Based in Parma, Italy, Chiesi Farmaceutici is an international research-focused healthcare group with 85 years of experience in the pharmaceutical industry and a global presence in 29 countries. Chiesi researches, develops, and markets innovative drugs in the respiratory therapeutics, specialist medicine, and rare disease areas. Its R&D organization is headquartered in Parma (Italy), and is integrated with R&D groups in France, the USA, the UK, and Sweden to advance Chiesi's pre-clinical, clinical, and registration programs. Chiesi employs nearly 6,000 people. Chiesi Group is a certified Benefit corporation. For more information, please visitwww.chiesi.com.

Chiesi Group Media ContactValentina BiaginiSenior Group Communication Manager Chiesi Groupv.biagini@chiesi.com

Chiesi USA Media ContactJenna UrbanBERRY & COMPANY PUBLIC RELATIONS, LLCT: 212 253-8881jurban@berrypr.com

PP-EF-0063 V1.0

PDF available:http://ml.globenewswire.com/Resource/Download/efd466cf-658c-4f9e-b113-e976dbace967

Read more here:

Chiesi Global Rare Diseases Announces First Patient Treated in Expanded Access Program for Pegunigalsidase Alfa for Proposed Treatment of Fabry...

Cannabis and pain management: Is alternative plant medicine becoming the new norm? – The GrowthOp

Article content continuedAs time goes on, alternative plant medicine is slowly contributing to a change in the way pain management is viewed and/or executed. / Photo by BLAIR GABLE /REUTERS

For example, NSAIDs can be beneficial, but theyve also been associated with complications involving the gastrointestinal, cardiovascular and renal systems. For their part, opioids have proven their effectiveness in different situations, but have also demonstrated their potential to cause cognitive deficiencies, motor impairment and respiratory depression. Opioids also, unfortunately, represent a substantial addiction and dependency risk among specific groups of individuals.

As time goes on, alternative plant medicine, such as cannabis, numerous cannabinoids and terpenes, are slowly contributing to a change in the way pain management is viewed and/or executed.

The cannabis plant contains over 100 cannabinoids, but some of them are more well-known than others, including CBD and THC. Numerous cannabinoids are medically and therapeutically beneficial in multiple ways, but CBD, THC, cannabichromene (CBC) and cannabigerols (CBG) analgesic properties stand out. So far, it has been found that CBC contains both anti-inflammatory and analgesic properties, while CBG has been shown to have stronger analgesic activity than THC.

Aside from the analgesic properties of different cannabinoids, various terpenes found in the cannabis plant are analgesics as well, especially myrcene. One 2008 study expanded on this, stating that: Myrcene is analgesic, and such activity, in contrast to cannabinoids, is blocked by naloxone, suggesting an opioid-like mechanism. Another terpene that contains analgesic and anti-inflammatory attributes is -caryophyllene.

In addition, cannabinoid analgesics have generally been well-tolerated in clinical trials. The World Health Organization (WHO) also reported that CBD is non-psychoactive, non-toxic and non-addictive, as well as has a good safety profile.

Although theres more to learn about cannabinoids and pain management, various surveys of cannabis users have shed light on the substitution of cannabis products for opioids. Specifically, one 2017 survey focused on U.S. and Canadian cannabis users. The following was reported: Our findings are consistent with prior surveys of American and Canadian marijuana users in which substitution of marijuana for opioids was prevalent due to better symptom management and fewer adverse and withdrawal effects.

Read this article:

Cannabis and pain management: Is alternative plant medicine becoming the new norm? - The GrowthOp

Dept pushing for cannabis use in Thai traditional medicines – Bangkok Post

The Department of Thai Traditional and Alternative Medicine is pushing for the use of medical cannabis in traditional Thai medicines, with plans to cultivate the cannabis plant at 150 Tambon Health Promoting Hospitals nationwide.

Director-General of the Department of Thai Traditional and Alternative Medicine, Amporn Benjaponpitak, has declared the department's use of cannabis with Thai traditional medicine in the 2020 fiscal year a success.

Dr Amporn said the Public Health Ministry had included medical cannabis in its service plan for the 2020 fiscal year.

This was in line with the government's policy to make further use of local wisdom and knowledge to develop innovative processed agricultural products.

It is also the government's policy to promote research and development on medical cannabis to add economic value to the plant, said Dr Amporn.

For the 2021 fiscal year, the department will focus on developing quality cannabis farms to generate income for people and ensuring there is a sufficient supply of medication made with medical cannabis in the national healthcare scheme.

According to the department's chief, the department has piloted a project to cultivate cannabis at Tambon Health Promotion Hospitals in collaboration with community enterprises.

In the project's first phase, medical cannabis will be cultivated for the production of traditional Thai medicine. Three hospitals have already cultivated cannabis plants.

The second phase is aimed at increasing the number of medical cannabis farms to 150 nationwide.

Presently, 54 hospitals in 20 provinces and 11 health areas have received a licence to cultivate cannabis from the narcotic drugs committee.

In the third phase, medical cannabis will be used to treat palliative care patients. The goal of this phase is to promote the cultivation of medical cannabis by community enterprises.

Dr Amporn added that the department's medical cannabis plan for the 2021 fiscal year had the objective of developing legal cannabis farms for the production of traditional Thai medicine, educating people about legal medical cannabis and increasing health options for people.

Meanwhile, Justice Minister Somsak Thepsutin disclosed that the draft of the Kratom (Mitragyna speciosa) Act is in its second reading stage by a committee chaired by himself.

The Kratom Act draft is expected to be reviewed by parliament in early 2021.

Read the rest here:

Dept pushing for cannabis use in Thai traditional medicines - Bangkok Post

Eating This One Food Every Day May Help Weaken COVID-19 – Yahoo Lifestyle

This year has been a crash-course in COVID knowledge. In January we had a vague understanding of the virus; 12 months later, we can recite the best ways to avoid exposure, rattle off nearby testing centers, and run through common symptoms from memory. And, as vaccination looms in the not-so-distant future, we continue to learn more about how best to fight and weaken COVID-19. Based on new research and expert opinion, you might consider armoring yourself with an ancient superfood: mushrooms.

Here's why, and for more COVID-related tips, here's The One Vitamin Doctors Are Urging Everyone to Take Right Now.

Perhaps one of the most polarizing foods in terms of taste, doctors, and nutritionists agree that mushrooms can provide a vital boost against COVID-19.

Jenny Bennett, a naturopathic doctor in Seattle with a focus on immune-mediated conditions, says that both shiitake and maitake mushrooms are "phenomenal for immune system enhancement."

"Shiitake especially," she says. "There is a ton of research on how it reduces viral activity, and can actually reduce the amount of virus in your body."

Mushrooms naturally inhibit viral enzymes, according to studies like those cited in the Mayo Clinic Book of Alternative Medicine, but their superpowers don't end there. They can also slow viral uptake, meaning you might actually get less sick and see symptoms progress at a slower rate if you incorporate mushrooms into a regular diet.

Beyond their direct benefits, mushrooms also help your body by stimulating an immune response in generalthere's evidence that they promote biochemical factors (i.e. alkalinity) that help prevent viral replication.

So when's the right time to make mushrooms a part of your diet?

"They're best taken the moment you feel the symptoms," Dr. Bennett advises. "You always get the best effects when you take them immediately, and taking them early will reduce symptoms progressing further."

Story continues

In the name of being preventative rather than reactive, you might consider incorporating mushrooms into meals now, regardless of whether or not you've contracted COVID-19. For those of us who aren't inherent fans of the health staple, nutritionist Sharon Katzman offers advice on how to make them more appetizing.

If you're more mushroom-averse, she says, you can buy dry or powdered varieties and sprinkle them into other dishes. Or, if you're into soups, try adding mushrooms to your favorite broth.

Dr. Bennett adds that it's also effective to buy mushrooms fresh and sautee them in butter or a bit of oil.

"Or, you can steep them as teas," she says, with a laugh. "They actually don't taste terribly fungal."

Mushroom tea may sound unappetizing, but when taken with a side of 2020, maybe it's the most fitting beverage we've had all year. You could also try one of these 23 Healthy Mushroom Recipes.

Read more here:

Eating This One Food Every Day May Help Weaken COVID-19 - Yahoo Lifestyle

Alternative and Complementary Medicine Market In-Depth Analysis & Forecast 2017-2025 – NeighborWebSJ

Complementary and alternative medicine (CAM) refers to medical products and practices that are not part of mainstream practices. While complementary medicine can be used along with mainstream medical practices, alternative medicine are used in place of standard medical treatments. Some CAM therapies have been found to be safe and effective unlike some that have been found to be ineffective or possibly harmful.

Get Exclusive PDF Sample Copy Of This Report:https://www.tmrresearch.com/sample/sample?flag=B&rep_id=2531

Complementary and alternative medicine includes a host of botanicals and nutritional substances such as herbal supplements, dietary supplements, and vitamins. A large number of CAM products are regarded to be safe as they are produced by nature or are present in nature. However, this may not be necessarily true for all natural products. In addition, some naturally sourced medicines may affect the action of other medicines. For instance, St. Johns wort a herb which is used for depression may interfere with the way certain anticancer drugs work.

Herbal supplements can have unwanted effects when used on their own, in combination with other drugs, or in large doses. Vitamins can also be harmful on the body. Too much of vitamin can be detrimental on health, even in a healthy person. Supplements do not need approval from federal government before being commercially available.

Patients of chronic diseases who are considering using complementary or alternative medicine need to talk to their doctor or nurse. This is because some therapies of complementary and alternative medicine may interfere with mainstream medicine or can be also be harmful. The claims of efficacy of complementary and alternative medicine therapy needs to be ascertained before bringing into use.

Global Alternative and Complementary Medicine Market: Overview

The global market for alternative and complementary medicines is projected to experience substantial growth in the next few years. The rising expenditure of the healthcare facilities is considered as the major factor that is likely to encourage the growth of the overall market in the coming years. In addition, the increasing number of initiatives being taken by Governments across the globe to promote alternative and complementary medicines is projected to accelerate the markets growth. Thanks to these factors, the global alternative and complementary medicine market is likely to exhibit a promising growth rate in the near future.

Buy This Report @https://www.tmrresearch.com/checkout?rep_id=2531<ype=S

Global Alternative and Complementary Medicine Market: Key Trends

A significant rise in the number of initiatives by NGOs and government organizations to encourage the use of alternative and complementary medicines is estimated to bolster global market in the near future. In addition to this, technological advancements in this field and the rising inclination of consumers towards these medicines and practices are likely to offer lucrative growth opportunities for the leading players operating in the alternative and complementary medicine market across the globe. However, the lack of scientific results is expected to hamper the overall growth of the market in the next few years.

Global Alternative and Complementary Medicine Market: Market Potential

Alternative and complementary medicines make use of several tradition methods to help the patients, most of which are not completely supported scientifically. As a result, the use of these medicines in several developed economies is comparatively less. Nonetheless, with a rising focus on research and development activities in order to find clinical support and the emergence of new methods and medicines are anticipated to encourage the growth of the global alternative and complementary medicine market throughout the forecast period.

Global Alternative and Complementary Medicine Market: Regional Outlook

From a regional perspective, Europe is considered as one of the leading segment, thanks to the significant revenue contribution in the last few years. This region is expected to account for a large share of the global alternative and complementary medicine market with the rising use of botanicals. In addition to this, the increasing awareness among consumers regarding the availability of effective alternative and complementary medicines and the benefits they offers are expected to encourage the growth of the Europe market in the coming years.

Furthermore, with the rising popularity of medical tourism, the alternative and complementary medicine market in Asia Pacific is projected to witness a steady growth in the next few years. Moreover, the presence of a large number of new players operating in this region is likely to offer promising growth opportunities over the forecast period. The Middle East and Africa segment is anticipated to experience a healthy growth in the alternative and complementary medicine market in the near future.

Global Alternative and Complementary Medicine Market: Competitive Analysis

The global market for alternative and complementary medicines is presently at a highly competitive stage and is predicted to experience an intense level of competition among the leading players in the coming years. The prominent players in the market are focusing on the expansion of the product portfolio so as to attract a large number of consumers across the globe. This is likely to help them in creating a brand name and acquiring a leading position in the global market. Some of the leading players operating in the alternative and complementary medicine market across the globe are Herb Pharm, Yoga Tree, Quantum Touch Inc., Helio USA Inc., Pure encapsulations, Inc., Pacific Nutritional Inc., Deepure Plus, Herbal Hills, Iyengar Yoga Institute, The Healing Company, and Nordic Naturals.

To know more about the table of contents, you can click @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=2531

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Link:

Alternative and Complementary Medicine Market In-Depth Analysis & Forecast 2017-2025 - NeighborWebSJ

Ashwagandha, Ayurvedic super herb that helps you look younger and live longer just ask Meghan, Jennifer Aniston and Gwyneth Paltrow – AsiaOne

Do you want to sleep better, look younger and live longer? Your answer may lie in a wonder herb thats been used in Indian traditional medicine, or Ayurveda, for thousands of years: Withania somnifera, or ashwagandha.

Also called Indian ginseng or winter cherry, its name is derived from the Sanskrit words ashwa, meaning horse, and gandha, meaning smell, referring both to the unique musky smell of its roots, reminiscent of a stallion, and its ability to give horse-like strength and vitality.

Ashwagandha is a small shrub with yellow flowers, a member of the night shade family. While every part of the plant is useful, its the stout, fleshy roots that are sought after as a supplement, either powdered or added to a tincture, and available as powder or in capsules.

Now popular the world over American celebrities Gwyneth Paltrow, Jennifer Aniston and Meghan Markle have this wonder herb in their repertoire it has been found to aid in curing ailments from weakness to infertility.

In Ayurveda, ashwagandha was identified as a rasayana thousands of years ago a herb that improves tissue health and rejuvenates you in the process, says Sheela Rani Chunkath, retired chief secretary of the Indian state of Tamil Nadu, and a columnist who writes about Ayurveda.

Ashwagandha is one of the most commonly used herbs in Ayurveda, for the vata constitution, which is associated with air and space. Balanced vata energy helps maintain supple skin and joints, a healthy body weight, healthy cognitive function and a healthy nervous system.

Commonly available as a churna , a finely sieved powder that can be mixed with ghee (clarified butter) or milk, ashwagandha is traditionally taken with ghee and honey. The powder can also be mixed into energy balls, smoothies and lattes.

Dhananjay Sharma, president of one of Indias oldest Ayurvedic companies, Shree Baidyanath Ayurveda Bhawan, describes the herb as an adaptogen, a combination of amino acids and vitamins, that gives it the ability to adapt to both physical and mental stress in the environment by reducing cortisol levels.

According to the Kama Sutra , the Indian treatise on sex, ashwagandha is a potent sexual stimulant. Studies show the herb may increase testosterone production and boost sperm health.

Ashwagandha has long been a favourite with athletes for helping build strength and endurance and aid recovery, and studies suggest it can improve the brains memory functions including attention and concentration. It appears to slow the degeneration of brain function in people with diseases such as Alzheimers and Parkinson, according to a 2011 report in the African Journal of Traditional, Complementary and Alternative Medicine .

The herb can energise and calm at the same time. Chyawanprash, a nerve tonic thats been used by Indians for years as a health booster, contains ashwagandha. A study published in the journal Phytomedicine in 2000 showed that the herb had the ability to reduce anxiety levels, as did another in 2012 published in the Indian Journal of Psychological Medicine .

The second part of its botanical name, Withania somnifera, translates as sleep-inducing, and reflects its relaxing and calming properties. It can be used at bedtime and has been shown to induce restful sleep , without the drowsiness associated with sleep medications.

Ashwagandha may help prolong youth, and preserve beauty. It is used as a hair mask, to strengthen the roots of the hair, and as a paste with dried ginger and lemon peel to cure acne. It has high levels of antioxidants that stave off free radicals to fight signs of ageing such as wrinkles, dark spots, fine lines and blemishes. A liquid mixture of ashwagandha can be applied as an ointment to treat cuts, bruises and skin inflammation.

The herb also has a high concentration of withanolides, naturally occurring steroids that studies suggest fight inflammation and tumour growth. While it is used as a complementary treatment to ease the fatigue and pain from chemotherapy, scientists are keenly exploring whether it might aid directly in the fight against cancer .

Now research shows this powerful herb also has the potential to help stop the coronavirus pandemic .

The Indian Institute of Technology at Delhi and Japans National Institute of Advanced Industrial Science and Technology, in a collaborative study, discovered that an efficient natural compound found within ashwagandha may be effective in developing a drug to fight the coronavirus.

The study, published online in the Journal of Biomolecular Structure Dynamics in June, concluded: Ashwagandha stem may provide preventive and therapeutic benefits in the current pandemic.

Another study by researchers at the All India Institute of Medical Sciences, published in the same journal in July, came to similar conclusions: The status of Withania somnifera as an immunity enhancer, anti-diabetic agent and blood pressure and hormonal regulation is well known. The present study suggests that additionally, the Ayurveda herb ashwagandha could prove to be an alternative to available treatments of Covid-19.

Despite its myriad benefits, ashwagandha is not for everyone. Pregnant women should not take it. It may aggravate autoimmune diseases such as rheumatoid arthritis. Having too much of this herb may irritate the gastrointestinal tract.

This article was first published in South China Morning Post.

View original post here:

Ashwagandha, Ayurvedic super herb that helps you look younger and live longer just ask Meghan, Jennifer Aniston and Gwyneth Paltrow - AsiaOne

Immunotherapy Continues on Positive Trajectory in Lymphoid Malignancies – OncLive

The treatment landscape of lymphoid malignancies space is rich with available immunotherapy agents, said Joshua Brody, MD. However, the field continues to push toward improving response rates by refining established modalities, such as CAR T-cell therapy and checkpoint inhibitors, as well as introducing novel modalities.

During the5th AnnualInternational Congress on Immunotherapies in Cancer, a program run by Physicians Education Resource (PER), Brody, an assistant professor of medicine, hematology, and medical oncology and director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at Mount Sinai, gave a presentation on established and upcoming immunotherapies in the lymphoid malignancy pipeline.

We are somewhat lucky, and maybe a bit spoiled in lymphoid malignancies, such as lymphomas and some B-cell malignancies, to have [seen] a huge amount of progress [with immunotherapy], said Brody.

However, lymphoid malignancies are highly heterogeneous. As such, not all patients are able to derive responses from the same therapy, Brody explained.

CAR T-cell therapy represents a significant advance in the treatment paradigms of several hematologic malignancies, including lymphoid malignancies, said Brody.

The results [of CAR T-cell therapy treatment] for patients with aggressive B-cell lymphomas have been amazing, Brody said. [CAR T-cell therapy] has shown higher response rates [in this space] than any other immunotherapy for any type of cancer; response rates are above 80%. Many of those [responses] are long lasting, complete remissions [CRs].

Notably, it is thought that patients who remain in CR for at least 6 to 12 months after CAR T-cell therapy infusion are likely cured of their lymphoma, Brody said. For example, it is likely that around 35% to 40% of patients with diffuse large B-cell lymphoma (DLBCL) who receive CAR T-cell therapy are effectively cured.

Third-line [DLBCL], the most common type of lymphoma, [was thought to be] an incurable disease setting, said Brody. We [thought we could] cure people in the first- or second-line setting, but not beyond. Im not sure how we define a miracle, but it seems miraculous to me to change the incurable to partly curable.

Now, ongoing research efforts are attempting to refine CAR T-cell therapies to enhance responses and expand the utility of the modality to other hematologic malignancies beyond DLBCL, acute leukemia, and mantle cell lymphoma, explained Brody. For example, developing armored CAR T cells and fourth-generation CAR T cellsT cellsredirected for antigenunrestricted cytokineinitiated killingmay allow for improved delivery of cytotoxic payloads to liquid as well as solid tumors.

Additionally, novel CAR T-cell therapies may overcome some of the ongoing challenges observed with current, autologous products, such as toxicity, accessibility, and feasibility. For example, utilizing an allogeneic approach to CAR T-cell therapy may allow for an off-the-shelf option that could alleviate the risk of cytokine release syndrome and neurotoxicity.

Beyond CAR T-cell therapy, bispecific monoclonal antibodies, such as the investigational CD20/CD3-directed REGN1979 agent, could potentially be used in patients who progress after CAR T-cell therapy. Findings from a phase 1 trial (NCT02290951) demonstrated high objective response rates and CR rates among patients with heavily pretreated, relapsed/refractory NHL who were treated with REGN1979.1

Although the toxicity challenges of CAR T-cell therapies are likely not going to be solved with bispecific antibodies, the novel agents may offer an alternative option that can decrease the risk of adverse effects.

At least with [bispecific antibodies], we can tweak and optimize [dosing] a bit, explained Brody. CAR T-cell therapy is usually a one-shot therapy, [whereas] bispecifics can be given in low, medium, or high doses. We can up-titrate the therapy to try to minimize or avoid some of these toxicities.

Additionally, bispecific antibodies are potentially able to avoid antigen escape, which is a common concern with CD19/CD20-directed CAR T-cell therapies, Brody explained.

PD-1/PD-L1 inhibitors have transformed the treatment landscape in melanoma, lung cancer, renal cell carcinoma, and bladder cancer. However, Hodgkin lymphoma is the most responsive disease to antiPD-1 agents because chromosomal amplifications or translocations are hardwired to overexpress PD-1, Brody said.

As such, responses with checkpoint inhibitors, such as nivolumab (Opdivo), are seen in around 70% of patients with Hodgkin lymphoma who progress following autologous stem cell transplant.2

The introduction of checkpoint inhibitors to this space has been particularly encouraging for younger patients who fail curative-intent chemotherapy and who, historically, had dismal prognoses.

Currently, ongoing efforts are attempting to bring PD-1 inhibitors to the second-line setting and, potentially, up-front settings in combination with chemotherapy.

Although it is true that hot tumors are more likely to respond to immunotherapy compared with cold tumors, it is not the only factor that contributes to whether a tumor will respond. As such, alternative methods of improving immune response in patients with lymphoid malignancies are being evaluated.

For example, one investigational method is to utilize radiotherapy or other means to mobilize dendritic cells loaded with tumor antigens to antigen-presenting cells. Ultimately, this compound could serve as a therapeutic anti-cancer vaccine to deliver the antigens, as well as costimulatory signals, to the cancer cells.

As such, an ongoing trial (NCT03789097) led by Brody is currently testing an in situ vaccine combining radiation therapy, the immune cell growth factor Flt3L/CDX-301, the immune-cell activating factor Poly-ICLC, and pembrolizumab (Keytruda).3 Initial findings from the study have yielded encouraging results, according to Brody.

In situ vaccines such as this may be able to cross prime T cells and increase the effectiveness of immunotherapy for patients, Brody concluded.

See the rest here:

Immunotherapy Continues on Positive Trajectory in Lymphoid Malignancies - OncLive

How Mesothelioma Patients Cope with Having a Rare Disease – MesotheliomaHelp.org

We usually write about our experiences while caring for patients with malignant mesothelioma. As always I cannot remember when I left a patient and didnt have a new respect for how patients with rare diseases like mesothelioma deal with the impact on their lives. Today I read an article about a woman who had been stripped of her job, hobbies, and her life as she knew it by a rare disease other than malignant mesothelioma.

The unique perspective of rare diseases has always fascinated me how do people learn to live with their new normal? Some people make it look easier than others as many adapt to their new way of life. A rare disease is defined as one that affects fewer than 200,000 people across a broad range of possible disorders. Mesothelioma is a rare disease that affects roughly 3,000 cases per year. In the United States there are over 7,000 rare diseases that affect more than 30 million Americans.

Malignant mesothelioma changes daily life for both individuals and families. It can send them into depression and fill the individual and their loved ones with fear. This particular article spoke about how a woman learned photography to document her journey with the disease, her feelings, and to have a visual timeline. Through her foundation she is sharing how she is adopting her hobby of photography to share with others who are going through similar situations. Documenting her struggles and strengths has been rewarding to her own self-esteem and to others who are experiencing similar situations.

When life throws a curveball like mesothelioma it forces most to re-evaluate life and how you will cope with your new rare illness. Most people that we have met handle it with grace and dignity. Some are able to speak freely about their journey where others are not sure how to express what they are going through. Some people keep journals, while others reach out to other survivors, and some take up a new idea that they think will help themselves down this new road. These are just a few examples on how people deal with a rare disease. Some may take up photography or drawing or possibly walking.

If you continue to struggle there are many organizations that can help. One organization that I would like to mention would be NORD, the National Organization for Rare Diseases. There are many tools and resources available that may help you cope with your disease. You may have a rare disease but you are never alone. Feel free to reach out to mesothelioma programs or a member of the team like myself here at Mesothelioma Help Organization.

See the rest here:

How Mesothelioma Patients Cope with Having a Rare Disease - MesotheliomaHelp.org

Mesothelioma in 2020: Top 10 Stories on FDA Approvals, COVID-19 and More – Mesothelioma Guide

We will remember 2020 for many reasons, with the COVID-19 coronavirus pandemic at or near the top of the list.

In the mesothelioma community, it was a year of COVID-related stress and FDA-approved hope. It was filled with emerging treatments and therapies made available to mesothelioma patients, victims receiving their deserved compensation, brands turning away from the dangerous ingredient talc, and important developments among some of the top hospitals.

When the calendar flips to a new year, we should remember 2020 for all the progress it brought in fighting this rare and deadly cancer. Here are the top 10 mesothelioma stories from the past year.

This was the biggest news of 2020 for mesothelioma patients, doctors, researchers, caregivers, advocates and anyone else. The U.S. Food and Drug Administration (FDA) approved the immunotherapy combination for pleural mesothelioma. The approval is explicitly for unresectable cases, meaning those that cant be helped with surgery.

Opdivo and Yervoy brand names for nivolumab and ipilimumab, respectively increase survival by four months compared to chemotherapy. The combination is also safe compared to chemotherapy, causing mild rashes and manageable side effects in most cases.

The COVID-19 pandemic swept through the United States and elsewhere causing understandable anxiety and stress. The group most affected was people with pre-existing respiratory issues, such as mesothelioma.

The coronavirus attacks the lungs and pleural mesothelioma forms in the lining next to the lungs. Patients with mesothelioma tumors on the lungs are at risk of contracting a severe case of COVID-19. Their depleted respiratory health and struggling immune system leave the body susceptible to other diseases, such as this virus.

The U.S. House of Representatives appeared destined to approve an asbestos ban during its September session. That destiny was scrapped at the 11th hour due to partisan politics.

The House indefinitely delayed any vote on the Alan Reinstein Ban Asbestos Now Act, and theres no telling when the congress leaders will take up the issue again. The decision came down to semantics and fine-print language within the bill, which is an unfortunate reason to keep the door open for asbestos to continue affecting and killing thousands of Americans each year.

Dr. Abraham Avi Lebenthal started the Boston VA mesothelioma program a decade ago. Now, he has handed the reins to Dr. Hassan Khalil, the newest thoracic surgeon at Brigham and Womens Hospital in Boston.

Dr. Khalil spoke to Mesothelioma Guide about joining Brigham and Womens staff, plus taking over the VA program. He trained under three of the best mesothelioma specialists in the world: Dr. Lebenthal, Dr. Raphael Bueno and Dr. Marcelo DaSilva.

One of the top stories in 2019 was the FDA approving a tumor treating fields device for unresectable pleural mesothelioma. Since the approval around 19 months ago, the device has grown in popularity and accessibility.

The device, originally called the NovoTTF-100L System, was rebranded as Optune Lua. Its available in more than 70 hospitals spanning 28 states.

Once experts identified the link between talc and mesothelioma the common thread being asbestos Johnson & Johnson became one of the main characters in the ongoing controversy.

The company decided in May to discontinue the talc versions of those products in the U.S. and Canada. The massive stack of legal claims against the company was the main reason for the move.

Johnson & Johnsons Baby Powder and Shower to Shower Powder both rely on talcum powder, which comes from the mineral talc. Asbestos can contaminate talc and lead to mesothelioma for consumers, which led to tens of thousands of lawsuits

Johnson & Johnsons top officials likely didnt want to see another $750 million verdict from a mesothelioma case, which also led to them paying more than $100 million to settle 1,000 talc cancer claims.

Johnson & Johnson isnt the only company struggling with legal claims and negative press regarding its talc products. The Environmental Working Group tested cosmetics recently and found traces of asbestos in 15% of them, sounding alarms about the dangers of many products on the market.

Opdivo and Yervoy werent the first two immunotherapy drugs approved for mesothelioma in 2020. The FDA decided in June to approve Keytruda, the brand name for pembrolizumab.

The approval is for a small subset of patients who have high levels of PD-L1. This cancerous protein appears on mesothelioma tumors and subdues the immune system. However, Keytruda halts the proteins power and elevates the immune response against mesothelioma.

Dr. DaSilva left Brigham and Womens Hospital towards the end of 2019 to jump-start the new mesothelioma program at AdventHealth in Orlando. Early in 2020, he started putting together his team and seeing the first patients.

Despite the COVID-19 pandemic, Dr. DaSilva and the AdventHealth staff continued the International Mesothelioma Treatment Programs progress. He had eight patients by June, with five of them having surgery.

Schools and school districts in Pennsylvania have faced asbestos issues since last year. In 2020, though, the problems resulted in criminal charges.

Two former Scranton School District officials former superintendent Alexis Kirijan and former director of operations Jeffrey Brazil were charged with felony child endangerment. Then-current maintenance supervisor Joseph Slack was also charged.

Schools in Philadelphia closed at the start of 2020 due to widespread asbestos concerns. One city school district teacher was diagnosed with mesothelioma and connected her diagnosis to the unsafe working conditions in classrooms.

Sources & Author

Devin Golden is the content writer for Mesothelioma Guide. He produces mesothelioma-related content on various mediums, including the Mesothelioma Guide website and social media channels. Devin's objective is to translate complex information regarding mesothelioma into informative, easily absorbable content to help patients and their loved ones.

Get in depth knowledge about your diagnosis & the best treatments.

Learn More

See the rest here:

Mesothelioma in 2020: Top 10 Stories on FDA Approvals, COVID-19 and More - Mesothelioma Guide

Breakthroughs in Mesothelioma in 2020 – Surviving Mesothelioma

In spite of a global pandemic, there were some major breakthroughs in mesothelioma in 2020 that made the year a hopeful one for people fighting asbestos cancer.

Malignant mesothelioma is the most serious illness caused by exposure to asbestos fibers.

Mesothelioma is still not curable. But researchers have made major breakthroughs in mesothelioma diagnosis, prognosis, and treatment this year.

Mesothelioma treatment saw the biggest breakthroughs in mesothelioma in 2020. The FDA approved the first systemic treatment for mesothelioma since 2004. That was the year that Alimta (pemetrexed) received approval.

They approved a combination of the immunotherapy drugs Opdivo and Yervoy. Yervoy helps activate and proliferate T-cells. Opdivo helps existing T-cells discover the mesothelioma tumor. The patients who got the new drug combination for mesothelioma lived a median of 18 months.

At one year, almost 70 percent of patients who got the immunotherapy drugs were still alive. Only 58 percent of chemotherapy patients lived that long.

The second most important of the breakthroughs in mesothelioma treatment this year centers on Tumor Treating Fields. The electrical device received a new name in 2020. It is now Optune Lua. Optune Lua interrupts the replication of mesothelioma cells and stimulates the immune system.

This summer, the makers of Optune Lua and the immunotherapy drug Keytruda announced that they are teaming up for a new study. The study is testing a combination of these treatments in non-small cell lung cancer patients. The results are likely to impact the future of mesothelioma treatment, too.

One of the most significant breakthroughs in mesothelioma diagnosis was a biomarker study in July. That study appeared to confirm the best biomarkers for mesothelioma diagnosis and prognosis.

Two of the countrys top authorities on mesothelioma, Dr. Harvey Pass of New Yorks Langone Medical Center and Dr. Michele Carbone of the University of Hawaii, were authors on the new report.

They conducted a major review of medical literature over the last 20 years. They concluded that SMRPs (Soluble Mesothelin Related Proteins) are the best diagnostic biomarkers for mesothelioma. SMRPs are also the most valuable biomarkers for monitoring the success of mesothelioma treatment.

Other important diagnostic breakthroughs for mesothelioma were two reports on the use of artificial intelligence.

One study came from the Stevens Institute of Technology and the other from Mount Sinai Medical Center in New York. Both suggest that machine learning which can identify patterns that doctors miss may be the future of mesothelioma diagnosis and treatment planning.

International Immunopharmacology published the largest study ever on PD-L1 expression and mesothelioma prognosis. It showed that patients whose cells express more of this protein have lower odds of survival.

Programmed death ligand 1 (PD-L1) helps cancer cells evade immune system attack.

Other studies have suggested a link between PD-L1 expression and mesothelioma prognosis. But a meta-analysis performed by Chinese researchers confirmed it with an even bigger data set.

Another of the breakthroughs in mesothelioma prognosis also centered on protein expression. This time, BAP1 was in the spotlight. Alterations of the BAP1 gene affect BAP1 expression. People with low levels of BAP1 appear to have a higher risk for mesothelioma.

But a large Italian study released in July suggested that mesothelioma prognosis has more to do with subtype than with BAP1 expression. It cautioned doctors not to put too much stock in BAP1 expression without also considering other factors.

Sources:

FDA Approves Drug Combination for Treating Mesothelioma, FDA Press Announcement, October 2, 2020, https://www.fda.gov/news-events/press-announcements/fda-approves-drug-combination-treating-mesothelioma

Novocure Announces Clinical Trial Collaboration with MSD to Evaluate Tumor Treating Fields Together with KEYTRUDA (pembrolizumab) in Non-Small Cell Lung Cancer, July 15, 2020, Novocure Website

Choudhury, A, Predicting cancer using supervised machine learning: Mesothelioma, June 19, 2020, Technology in Health Care, https://content.iospress.com/articles/technology-and-health-care/thc202237

Dumane, VA, et al, RapidPlan for Knowledge-Based Planning of Malignant Pleural Mesothelioma, June 17, 2020, Practical Radiation Oncology, Epub ahead of print, https://www.practicalradonc.org/article/S1879-8500(20)30158-2/pdf

Pass, H, et al, Mesothelioma Biomarkers: A Review Highlighting Contributions from the Early Detection Research Network, July 22, 2020, Cancer Epidemiology, Biomarkers & Prevention, Epub ahead of print, https://cebp.aacrjournals.org/content/early/2020/07/22/1055-9965.EPI-20-0083

Zhang, F, and Gong, W, Prognostic and clinicopathological utility of programmed death-ligand 1 in malignant pleural mesothelioma: A meta-analysis, April 24, 2020, International Immunopharmacology, Epub ahead of print, https://www.sciencedirect.com/science/article/pii/S1567576920306639?via%3Dihub

Cantini, L, et al, Questioning the Prognostic Role of BAP-1 Immunohistochemistry in Malignant Pleural Mesothelioma: A Single Center Experience With Systematic Review and Meta-Analysis, June 21, 2020, Lung Cancer, Epub ahead of print, https://www.lungcancerjournal.info/article/S0169-5002(20)30498-0/pdf

See original here:

Breakthroughs in Mesothelioma in 2020 - Surviving Mesothelioma

Galinpepimut-S Shows Early Promise With Checkpoint Inhibition for 2 WT1-Positive Solid Tumors – Targeted Oncology

Encouraging early data were observed with galinpepimut-S (GPS), the Wilms Tumor-1 (WT1)-targeting peptide immunotherapeutic, in combination with immune checkpoint inhibitors as treatment of patients with 2 different solid tumor types who had exhausted standard therapeutic options, announced SELLAS Life Sciences Group, Inc.

GPS in combination with pembrolizumab (Keytruda) induced promising disease control rate (DCR) and progression-free survival (PFS) data in patients with advanced WT1-positive ovarian cancer, while GPS combined with nivolumab (Opdivo) generated clinically intriguing activity in patients with mesothelioma.

These early data confirm the tolerability profile seen in earlier studies of GPS, which is one of the primary endpoints in these solid cancer trials, in a variety of cancer indications, even in the most refractory patients who underwent numerous prior therapies, said Jeffrey S. Weber, MD, PhD, deputy director of the Perlmutter Cancer Center at New York University (NYU)-Langone Health, co-director of its Melanoma Research Program Center and Chair of SELLAS Scientific Advisory Board, in a statement. These safety findings are accompanied by promising early indications of an efficacy signal for patients with advanced metastatic disease, whose management is extremely challenging even with checkpoint inhibitor monotherapy.

The first study is a phase 1/2 basket trial of GPS plus pembrolizumab, and the first set of evaluable patients had second- or third-line WT1-positive relapsed/refractory metastatic ovarian cancer. Among these 8 patients, the DCR was 87.5% with a median follow-up of 9.4 weeks. At 6 weeks, all patients were free of disease progression for a PFS rate of 100%.

The rate of WT1-positivity was approximately 70% during the screening period, according to findings using a validated immunohistochemistry (IHC) assay. Six of the patients are still receiving therapy on the study, and the target enrollment is 20 patients.

The second study, a phase 1 investigator-sponsored study of GPS with nivolumab, included 3 patients with macroscopic measurable deposits of malignant pleural mesothelioma (MPM) who were wither refractory to or relapsed after first-line tri-modality standard therapy in the first set of evaluable patients. These patients had a median PFS of at least 10 weeks since the start of therapy. Considering the lack of effective treatments for patients with primary refractory disease, PFS prolongation is considered clinically meaningful when the interval is greater than 8 weeks.

All patients in the study had the epithelioid variant of MPM which is a tumor that universally expresses WT1. GPS appeared to be appropriately immunogenic, which led to the emergency of WT1-specific CD4-positive T-memory cell responses 3 months post-initiation of treatment. A total of 10 patients with MPM are expected to enroll to the trial to complete the target recruitment.

The safety profile of both GPS regimens was similar to what has been observed previously with checkpoint inhibitors alone. The addition of this therapy induced only low grade, transitory local reactions at the site of injection, which is consistent with findings from previous clinical trials.

By the end of the second quarter of 2021, the company expects to have more mature clinical and immunobiological data from both of these clinical trials.

We are encouraged by the data shown in these 2 studies of GPS in combination with checkpoint inhibitors and look forward to additional data from these studies, stated Dragan Cicic, MD, senior vice president, Clinical Development of SELLAS. We now have early evidence that supports further expanding the field of potential GPS indications into solid cancers with high rates of WT1 positivity. GPS has previously been shown to invoke multi-epitope, broad cross-reactivity along the full-length of the WT1 protein, suggestive of epitope spreading, and immunologically mediated cancer cell destruction, which are hallmarks of an effective cancer vaccine. The scientific rationale in combining GPS with checkpoint inhibitors is the immunbiologic and pharmacodynamic synergy between the two agents, whereby the negative influence of the tumor microenvironment is mitigated by checkpoint inhibitors and thus allowing the patients own immune cells specifically sensitized against WT1, by GPS, to invade and destroy cancerous cells.

References

SELLAS announces promising initial clinical data for galinpepimut-S (GPS) in combination with checkpoint inhibitors in two solid tumor indications. News Release. SELLAS Life Sciences Group. December 21, 2020. Accessed December 22, 2020.

Read the original:

Galinpepimut-S Shows Early Promise With Checkpoint Inhibition for 2 WT1-Positive Solid Tumors - Targeted Oncology

Thunder Bay Therapy and Sports Medicine to get new look, new name – Alpena News

News Photo by Crystal NelsonThunder Bay Therapy and Sports Medicine owners Teresa and Bruce Duncan demonstrate their balancing equipment earlier this month at the location in Alpena.

ALPENA Thunder Bay Therapy and Sports Medicine will be unveiling a new look this spring, after joining forces with a nationally renowned physical therapy franchise.

Owners Bruce and Teresa Duncan recently signed an agreement with Fyzical Therapy and Balance Centers. The company has more than 400 locations throughout the United States, Teresa Duncan said, with the closest franchises currently located in Petoskey and Traverse City.

The business will be changing its name to Thunder Bay Fyzical Therapy and Balance Centers as part of the agreement, but the Duncans will retain ownership, and all of their employees will continue to work there.

Bruce Duncan said Fyzical Therapy and Balance Centers will provide more supportive services, which will provide them with more advanced training in both the clinical and business side of operations.

One of the issues weve run into for probably the last five years, its become increasingly complex of a landscape and we really needed a partner to help us through some of the regulatory issues that are part of health care, he said.

He said Fyzical was really the only option that worked for them, because the group offered them help. Other franchises would have bought their business and taken it over, which is not what the Duncans wanted.

Additionally, he said they wanted to maintain their independence so they can treat people in the manner they find best.

It was very important to us that we be able to retain ownership and all decision making and Fyzical met that need, Teresa Duncan said. It was also very important that we be able to grow this even more so it lasts a very time both for our community and for our employees.

Bruce Duncan said Thunder Bay Therapy already does some balance work, but they found Fyzical offered both training on the clinical end and on the business end to expand what they do for balance and distribution care.

The additional training for balance and distribution care is just one of the areas Fyzical will help the business expand into. Teresa Duncan said they want to become the place that people think of when they need specialized physical therapy or sports medicine.

The Duncans said they originally planned to go public with the change in the summer, but the coronavirus pandemic slowed their plans down terribly.

In the meantime, Teresa Duncan said the business changed its paint scheme to match the new branding. Theyve also received new equipment and staff have been attending clinical training. She said she expects the new signage to go up just after the first of the year.

Bruce Duncan said the agreement with Fyzical will allow the business to continue to move forward and meet the Duncans goals.

As weve grown, we want to expand services into areas that people normally have to go downstate for, or across the state for, he said. We really want to become a center of excellence, where people say, Im going to Alpena because they have this clinic, as opposed to, well get the basics here and then go down to Ann Arbor.'

Today's breaking news and more in your inbox

See the original post here:

Thunder Bay Therapy and Sports Medicine to get new look, new name - Alpena News